VetMedOsteoarthritis pain in dogs: bedinvetmab (Librela) vs placebo — LIKELY
In dogs with osteoarthritis pain, does monthly subcutaneous bedinvetmab improve owner-assessed pain scores vs placebo?
Shelf #181 · gate-verified and displayed under the developer's blinded-trial rule
LIKELY: Two large, randomised, double-blind, placebo-controlled multisite trials agree that monthly subcutaneous bedinvetmab gives more owner-assessed treatment success than placebo in dogs with osteoarthritis pain — day-28 Canine Brief Pain Inventory success 43.5% vs 16.9% (Corral 2021, 287 dogs) and 47.4% vs 36.6% (Michels 2023, 272 dogs), with benefit building over the first three monthly doses (day-84 number needed to treat 4.3 in Michels). The effect is real but not large: depending on study and time point, roughly one extra success for every 4 to 9 dogs treated. Trial adverse events were similar between groups; the unresolved question sits outside the trials — post-marketing pharmacovigilance reports of musculoskeletal adverse events (Farrell 2025), which are reporting-rate data, not trial evidence, and are carried on this shelf as a watch-out, not as an efficacy card. Drafted Nov 10, 2026 (VetMed build, topic #181); all figures from abstracts fetched and verified at drafting.
Corral 2021: day-28 CBPI treatment success 43.5% on bedinvetmab vs 16.9% on placebo (287 dogs)
Prospective, randomised, double-blind, placebo-controlled multisite study
Who: Dogs: 287 client-owned dogs with osteoarthritis, randomised 1:1 to monthly subcutaneous bedinvetmab 0.5–1.0 mg/kg (n = 141) or saline placebo (n = 146). The primary endpoint was treatment success on the owner-assessed Canine Brief Pain Inventory (CBPI) at day 28 — success defined as a ≥1-point reduction in pain severity score and a ≥2-point reduction in pain interference score (each 0–10). Bedinvetmab is a canine monoclonal antibody targeting nerve growth factor.
Result: Treatment success at day 28 was 43.5% on bedinvetmab vs 16.9% on placebo (p = 0.0017), and success was significantly greater on bedinvetmab from day 7 through every assessed time point (p ≤ 0.0025); success at days 56 and 84 was 50.8% and 48.2% on bedinvetmab vs <25% on placebo at all time points. Bedinvetmab showed a significant effect on all three CBPI components — pain interference, pain severity, and quality of life. Adverse health events occurred at similar frequencies in both groups, were considered typical for a population of dogs with osteoarthritis, and were not related to study treatment. In a single-armed open-label continuation phase, 89 responding dogs received up to six additional monthly doses with sustained efficacy.
Watch out: The endpoint is owner-assessed pain — the right measure for pain, but subjective, and this trial's placebo success rate (16.9%) was much lower than the US study below (36.6%). A manufacturer-conducted registration study. Post-marketing musculoskeletal adverse-event reports are a separate question the trials cannot answer — see the synthesis card.
Corral MJ, Moyaert H, Fernandes T et al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg. 2021;48(6):943-955. PMID: 34565678. Registry ID: none in the record. MeSH: Animals · Antibodies, Monoclonal · Dog Diseases · Dogs · Double-Blind Method · Osteoarthritis · Prospective Studies · Quality of Life
Michels 2023 (US field study): day-28 success 47.4% vs 36.6% (p = 0.0410) — by day 84 the number needed to treat was 4.3
Prospective, randomised, double-blind, placebo-controlled multisite parallel-group field study
Who: Dogs: 272 general-practice client-owned dogs with osteoarthritis in a field study conducted in the United States of America, block-randomised 1:1 to monthly subcutaneous bedinvetmab 0.5–1.0 mg/kg (n = 135) or saline placebo (n = 137); day-28 CBPI treatment success was evaluable in 128 bedinvetmab and 131 placebo dogs. This study was conducted to support registration in the USA.
Result: Day-28 CBPI treatment success was 47.4% on bedinvetmab vs 36.6% on placebo (p = 0.0410; number needed to treat 9.3; standardised effect sizes 0.3 for both pain severity and pain interference), and bedinvetmab was significantly better than placebo at days 28, 42, 56 and 84. Success rose after the second dose and plateaued for bedinvetmab at day 42 while declining for placebo from day 84; by day 84 the NNT was 4.3, with effect sizes of 0.4 (pain severity) and 0.5 (pain interference). Bedinvetmab beat placebo on all CBPI components (pain interference, pain severity, quality of life). Adverse events were similar between groups and not considered treatment-related. Mean bedinvetmab half-life after the first dose was 19.1 (± 8.3) days.
Watch out: The day-28 gap (about 11 percentage points) is modest, and the placebo success rate (36.6%) was far higher than in Corral 2021 — owner expectation is part of what these trials measure, and the drug's advantage grows with continued monthly dosing rather than appearing in full at once. A manufacturer registration study. Post-marketing safety reports sit outside the trial data — see the synthesis card.
Michels GM, Honsberger NA, Walters RR et al. A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Vet Anaesth Analg. 2023;50(5):446-458. PMID: 37541934. Registry ID: none in the record. MeSH: Dogs · Animals · Quality of Life · Prospective Studies · Dog Diseases · Osteoarthritis · Pain · Antibodies, Monoclonal · Double-Blind Method
Synthesis: two large blinded trials agree on a real, moderate pain benefit — with a post-marketing joint-safety question still open
Synthesis
Who: Synthesis of the cards above: Corral 2021 (randomised, double-blind, placebo-controlled, 287 dogs) and Michels 2023 (randomised, double-blind, placebo-controlled US field study, 272 dogs).
Result: The efficacy answer is consistent across two large trials on two continents: monthly bedinvetmab produces more owner-assessed treatment success than placebo, the margin widening over the first three doses (day-84 NNT 4.3 in Michels) — roughly one extra treatment success for every 4 to 9 dogs treated, depending on study and time point. The safety context a clinician should hold alongside: a 2025 specialist-led disproportionality analysis of the EMA EudraVigilance database (Farrell et al., Front Vet Sci, PMID: 40417367) found ligament/tendon injury, polyarthritis, fracture, musculoskeletal neoplasia and septic arthritis reported approximately 9 times more frequently in bedinvetmab-treated dogs than for six comparator drugs with the same indication combined, and an 18-member expert panel adjudicating 19 suspected musculoskeletal adverse events unanimously suspected a causal association between bedinvetmab and accelerated joint destruction; the authors state their findings support recent FDA analyses and call for close clinical monitoring. Reporting rates cannot establish causation or incidence — but they are not nothing, and joint monitoring during treatment is the prudent reading.
Watch out: Both efficacy trials are manufacturer registration studies using owner-assessed endpoints; the Farrell analysis is pharmacovigilance (spontaneous reporting rates, subject to reporting biases) and rides on this shelf as safety context, not as a trial card. Neither trial was designed to detect slowly developing joint harm, so the trials' clean adverse-event tables and the post-marketing signal are not in direct contradiction — they answer different questions.
Synthesis of Corral MJ et al. PMID: 34565678; Michels GM et al. PMID: 37541934; safety context: Farrell M et al. PMID: 40417367. Registry IDs as on the individual cards.
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.